30 results
6-K
EX-99.1
GLPG
Galapagos NV
26 Aug 20
Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress
6:37am
EXHIBIT 99.1
Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress
Featuring … the presentation of new insights on idiopathic pulmonary fibrosis (IPF) at the virtual European Respiratory Society (ERS) International Congress 2020.
IPF
6-K
EX-99.1
GLPG
Galapagos NV
21 Jan 21
Current report (foreign)
7:49am
: January 2021
2 National Rheumatoid Arthritis Society. What is RA? Available at https://www.nras.org.uk/what-is-ra-article Accessed: January 2021
3 … by RA? Available at NRAS - National Rheumatoid Arthritis Society Accessed: January 2021
9 KCL. (2018). Mental health linked to disease flare
6-K
EX-99.1
GLPG
Galapagos NV
24 Jan 20
Galapagos appoints Michele Manto as Chief Commercial Officer
8:52am
will expand our team and capabilities to bring Galapagos science to patients and society. I am in the fortunate position of working for a company
6-K
EX-99.1
GLPG
Galapagos NV
1 May 18
Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018
8:26am
and bone with GLPG1972 in an osteoarthritis (OA) rat model at the Osteoarthritis Research Society International (OARSI) World Congress today in Liverpool
6-K
EX-99.1
GLPG
Galapagos NV
19 May 21
Current report (foreign)
6:00am
/arthritis/basics/rheumatoid-arthritis.html. Accessed September 2020.
National Rheumatoid Arthritis Society. The Burden of Rheumatoid Arthritis across
6-K
EX-99.1
zidn57 o1buu1
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
97w4 meolod1b
28 May 21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
6:00am
6-K
EX-99.1
ouxr9qv87 jbfce3
22 May 18
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
6:00am
6-K
EX-99.1
hicxt hobs2tsq07
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.1
mnu4ayoeqagbwgn
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
2f0md badp7mb6e
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
6-K
EX-99.1
5wlu52m9e76hw
28 Sep 20
Current report (foreign)
6:00am
6-K
EX-99.1
npku8
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
dzsg4zjb7dz901ov
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
skdvykm lthzd
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
8et6rnn
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.2
zk8e9s0pe83
6 Aug 20
Galapagos reports solid H1 2020 progress
4:01pm
6-K
EX-99.2
s84gseeeoq nxrt8t
11 May 20
Current report (foreign)
4:05pm
6-K
EX-99.2
wr6c6
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.2
g0r s0wowp4lg6s77hzx
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am